Press release
Chronic Hepatitis B Virus Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies
Chronic Hepatitis B Virus Pipeline
Chronic Hepatitis B Virus Overview
Hepatitis B virus is a small DNA virus that belongs to the "Hepadnaviridae" family. It is a vaccine-preventable liver infection caused by the HBV. A hepatitis B infection can result in either an acute infection or a chronic infection. When a person is first infected with the hepatitis B virus, it is called an "acute infection" and most healthy adults that are infected do not have any symptoms and are able to get rid of the virus without any problems. Moreover, some adults are unable to get rid of the virus after six months and are diagnosed with "chronic infection." In this condition, the immune system is not able to get rid of the hepatitis B virus and it still remains in their blood and liver.
"Chronic Hepatitis B Virus Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Hepatitis B Virus Market.
The Chronic Hepatitis B Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Hepatitis B Virus diagnosis requires the evaluation of the patient's blood for HBsAg, hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (HBcAb).
Some of the key takeaways from the Chronic Hepatitis B Virus Pipeline Report https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Chronic Hepatitis B Virus treatment therapies with a considerable amount of success over the years. Chronic Hepatitis B Virus Key players such as - Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, and others, are developing therapies for the Chronic Hepatitis B Virus treatment
• Chronic Hepatitis B Virus Emerging therapies such as - PBGENE-HBV, SBT8230, VIR-3434, RG634, RG7854, Pradefovir, and others are expected to have a significant impact on the Chronic Hepatitis B Virus market in the coming years.
• In September 2020, Ligand Pharmaceuticals started pradefovir treatment for the patients with chronic hepatitis b virus infections: a multi-center, double-blind, randomized, positive control, Phase III Study. Eligible HBeAg-positive or HBeAg-negative chronic hepatitis B patients will be stratified by historical antiviral treatment (untreated or treated) at the time of screening, and then randomly assigned to Pradefovir mesylate tablet group or tenofovir disoproxil fumarate tablet group at a ratio of 2:1
• In September 2019, Xi'an Xintong Medicine Research (Chinese license) reported positive results from a Phase II trial of pradefovir, showing good efficacy, safety and tolerability. At the dose of 75 mg, the reduction of DNA viral load, the percentage of no viral load detected, and HBeAg negative conversion rate were better than tenofovir disoproxil fumarate (TDF) after 24 weeks of treatment. Overall incidence of side effects was less than TDF and there was no renal or skeletal toxicity
Chronic Hepatitis B Virus Pipeline Therapeutics Assessment
• Chronic Hepatitis B Virus Assessment by Product Type
• Chronic Hepatitis B Virus By Stage and Product Type
• Chronic Hepatitis B Virus Assessment by Route of Administration
• Chronic Hepatitis B Virus By Stage and Route of Administration
• Chronic Hepatitis B Virus Assessment by Molecule Type
• Chronic Hepatitis B Virus by Stage and Molecule Type
DelveInsight's Chronic Hepatitis B Virus Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Chronic Hepatitis B Virus Drugs Under Different Phases of Clinical Development Include:
• PBGENE-HBV: Precision Biosciences
• SBT8230: Silverback Therapeutics
• VIR-3434: Vir Biotechnology
• RG6346: Dicerna Pharmaceuticals
• RG7854: Roche
• Pradefovir: Ligand Pharmaceuticals
Get a Free Sample PDF Report to know more about Chronic Hepatitis B Virus Pipeline Assessment- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chronic Hepatitis B Virus Pipeline Analysis:
The Chronic Hepatitis B Virus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Chronic Hepatitis B Virus treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
• Chronic Hepatitis B Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Chronic Hepatitis B Virus product details are provided in the report. Download the Chronic Hepatitis B Virus pipeline report to learn more about the emerging Chronic Hepatitis B Virus therapies at:
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Chronic Hepatitis B Virus Pipeline Market Drivers
• High prevalence of chronic Hepatitis B Virus infection
• Rising case of liver cancer and cirrhosis deaths due to Hepatitis B Virus infection
Chronic Hepatitis B Virus Pipeline Market Barriers
• Expensive Hepatitis B Virus treatment
• Limited access to the diagnosis of hepatitis B
Scope of Chronic Hepatitis B Virus Pipeline Drug Insight
• Coverage: Global
• Key Chronic Hepatitis B Virus Companies: Precision Biosciences, Silverback Therapeutics, Vir Biotechnology, Dicerna Pharmaceuticals, Roche, Ligand Pharmaceuticals, and others
• Key Chronic Hepatitis B Virus Therapies: PBGENE-HBV, SBT8230, VIR-3434, RG634, RG7854, Pradefovir, and others
• Chronic Hepatitis B Virus Therapeutic Assessment: Chronic Hepatitis B Virus current marketed and Chronic Hepatitis B Virus emerging therapies
• Chronic Hepatitis B Virus Market Dynamics: Chronic Hepatitis B Virus market drivers and Chronic Hepatitis B Virus market barriers
Request for Sample PDF Report for Chronic Hepatitis B Virus Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Chronic Hepatitis B Virus Report Introduction
2 Chronic Hepatitis B Virus Executive Summary
3 Chronic Hepatitis B Virus Overview
4 Chronic Hepatitis B Virus- Analytical Perspective In-depth Commercial Assessment
5 Chronic Hepatitis B Virus Pipeline Therapeutics
6 Chronic Hepatitis B Virus Late Stage Products (Phase II/III)
7 Chronic Hepatitis B Virus Mid Stage Products (Phase II)
8 Chronic Hepatitis B Virus Early Stage Products (Phase I)
9 Chronic Hepatitis B Virus Preclinical Stage Products
10 Chronic Hepatitis B Virus Therapeutics Assessment
11 Chronic Hepatitis B Virus Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Chronic Hepatitis B Virus Key Companies
14 Chronic Hepatitis B Virus Key Products
15 Chronic Hepatitis B Virus Unmet Needs
16 Chronic Hepatitis B Virus Market Drivers and Barriers
17 Chronic Hepatitis B Virus Future Perspectives and Conclusion
18 Chronic Hepatitis B Virus Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Chronic Hepatitis B Virus drugs and therapies- https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Chronic Hepatitis B Virus Market https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Hepatitis B Virus-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Chronic Hepatitis B Virus Epidemiology https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Chronic Hepatitis B Virus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Trending Reports:
Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.
Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027
To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Media Contact:
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
About US:
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies here
News-ID: 2753006 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
Automatic Balancing Valves Market Research Report 2017: IMI Hydronic, Danfoss, F …
In this report, the global Automatic Balancing Valves market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Request for sample of Automatic Balancing Valves Market research report @ https://www.qyresearchgroups.com/request-sample/365951
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate…
